Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization.

Conclusions For the first time different clinical, pathological features and outcome data are reported according to the 3 BRAF mutation classes in mCRC. Specific targeted treatment strategies should be identified in the next future for such patients.
PMID: 30967421 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 8, 2019 Category: Cancer & Oncology Authors: Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Rugge M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Tags: Clin Cancer Res Source Type: research